Indian Drug Makers See Benefits In U.S. Obama Administration
This article was originally published in PharmAsia News
Executive Summary
India's pharmas view the newly inaugurated Barack Obama administration in the United States as a good sign for their generics-dominated industry. The country already is the fourth largest generics supplier in the United States, which itself is the world's largest market at $33 billion a year. Indian firms are counting on Obama's promises to cut health care costs, in part by allowing importation of U.S.-approved drugs from other countries and an added emphasis on government coverage of generic versions. Indian pharmaceuticals also look forward to government efforts to remove obstacles they feel branded companies have managed to get put into place, including anti-tariff hurdles. (Click here for more
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.